“减肥神药”司美格鲁肽被曝或导致严重视力损伤，有患者已获赔偿

Core Viewpoint - Novo Nordisk's weight loss drug semaglutide has been linked to severe vision damage, with 43 patients filing for compensation in Denmark due to a rare side effect known as NAION [1][4][5] Group 1: Patient Compensation and Legal Proceedings - The Danish Patient Compensation Association reported that 43 patients experienced severe eye disease NAION after using Ozempic or Wegovy, with initial rulings on five cases resulting in four compensations [1][2] - The total compensation for the four patients is approximately 800,000 Danish kroner (about 878,000 RMB), with potential increases if patients suffer income loss due to NAION [4] Group 2: Medical and Regulatory Insights - NAION is a serious condition affecting the optic nerve, potentially leading to vision loss and is considered a rare side effect of semaglutide-containing drugs [4][5] - The Danish Medicines Agency issued a warning based on two large studies indicating a link between NAION and semaglutide, with the European Medicines Agency confirming this association in June 2025 [4][5] Group 3: Market and Usage Statistics - Despite the low incidence rate of NAION (less than 0.01%), the large patient population using semaglutide raises concerns about other complications and side effects [5] - By the end of 2025, it is estimated that over 50 million people globally will have used semaglutide, with approximately 22-25 million for diabetes treatment and 16-18 million for weight loss [5]